|
|
 |
|
Viewing report
|
|
|
|
Eisai Co., Ltd: PharmaVitae Profile
Datamonitor, Jan 2011, Pages: 76
Introduction
This analysis examines the historical and forecast performance for Eisai in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
Features and benefits
- Gain insight into Eisai's strategic outlook across the next 6 years
- Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source
Highlights
- Strategic insight into the prospects for Eisai over the next six years.
- Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.
Your key questions answered
- Benchmark Eisai's performance against key rivals in the prescription pharmaceutical sector
- See how the loss of patent protection on Eisai's blockbuster products Aricept and Pariet/AcipHex will impact Eisai's sales performance
- Evaluate Eisai's long-term growth potential following the acquisition of US companies Morphotek and MGI Pharma
|
|
|
|
